Targeted Oncology presents Case-Based Peer Perspectives. In each video, expert physicians provide insight on managing oncology-based patient cases that highlight the use of novel agents in clinical practice.
Management of Advanced Polycythemia Vera in a 67-year-Old Man
April 17th 2024Dr. Kuykendall discusses the case of a 67-year-old man with advanced polycythemia vera (PV) factors impacting selecting and sequencing of treatments like hydroxyurea, ruxolitinib, interferons, and emerging therapies.
Read More
Intermediate- 2 Risk Myelofibrosis in a 68-Year-Old Woman
April 17th 2024Dr. Bose discusses the case of a 68-year-old woman with intermediate-risk myelofibrosis, including his initial impressions of the case, the key factors he considers when selecting initial therapy, and his perspective on the efficacy and safety of JAK inhibitors based on clinical trial data. He also covers timing of ruxolitinib initiation, managing anemia in patients on ruxolitinib, preserving quality of life, and the unmet needs and emerging therapies in the management of intermediate myelofibrosis.
Read More
Chronic GvHD After RIC MRD HCT for AML with Post-Transplant Cyclophosphamide GvHD Prophylaxis
April 17th 2024Yi-Bin Chen, MD, presents an overview of graft versus host disease (GVHD), covering a patient case, first-line and second-line treatment options, associated toxicities, and the potential impact of ongoing clinical trials on the future of GVHD treatment.
Read More
Management of Elderly Transplant-Ineligible BPDCN Patient
April 15th 2024Dr. Schiller discusses the management of elderly transplant-ineligible patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), including an overview of the key clinical and pathologic features, the factors that make this patient population difficult to treat, and the limitations and potential future improvements in BPDCN treatments for this specific population.
Read More
Expert perspectives on the management of blastic plasmacytoid dendritic cell neoplasm (BPDCN) from a case-based peer discussion. The segments cover an overview of BPDCN, including clinical hallmarks and diagnostic challenges, as well as the appropriateness of initial therapy with tagraxofusp based on NCCN guidelines. The discussion explores the mechanism of action and potential efficacy of tagraxofusp, recent clinical trial data like the CADENZA study, and the potential of anti-CD123 CAR T-cell therapy for BPDCN. The segments also evaluate strategies for monitoring and mitigating adverse events, particularly capillary leak syndrome, quality of life considerations with various BPDCN treatments, and the future landscape with emerging research and limitations of current options, featuring insights from Dr. James K. McCloskey II.
Read More
Chronic GvHD MUD HCT for AML Despite Tacrolimus/Methotrexate Prophylaxis
April 1st 2024Dr. Cutler discusses the management of chronic graft-versus-host disease (cGvHD) in a 48-year-old man who developed cGvHD after undergoing a matched unrelated donor (MUD) hematopoietic cell transplantation (HCT) for acute myeloid leukemia (AML), despite receiving tacrolimus and methotrexate as prophylaxis.
Read More
A 75-Year-Old Man with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)
March 28th 2024Neal Shore, MD, FACS, analyzes a patient case involving a 75-year-old man with non-metastatic castration-resistant prostate cancer (nmCRPC) and explores recent trials that offer insights into patient sequencing and treatment selection for this condition.
Read More
A 57-Year-Old Man Diagnosed with Non-Clear Cell, Renal Cell Carcinoma (nccRCC)
March 4th 2024Dr. Robert Motzer shares his clinical perspectives and insights on the management of patients with nccRCC, including initial therapy considerations, emerging data on combination regimens, adverse events and the future landscape.
Read More
A 59-Year-Old African American Woman with Clear Cell, Renal Cell Carcinoma (ccRCC)
February 13th 2024Expert Hans Hammers, MD, reviews a case of a 59-year-old African American woman who underwent nephrectomy for left renal mass revealing clear cell RCC, who later developed metastatic disease managed initially with pembrolizumab and lenvatinib.
Read More
Bispecific Antibodies: Operationalizing Administration and Follow-Up
December 14th 2023Brooke Peters, PharmD, BCOP, shares her insight on institutional program development and operationalizing of bispecifics administration, highlighting its key components, roles involved, and clinical consideration for the management of related toxicities.
Read More
A 62-Year-Old Female with Stage IV BRAF-Mutated Melanoma
November 30th 2023Michael B Atkins, MD, discusses first-line treatment options for a patient with stage IV BRAF-mutated melanoma. He also reviews data that may help guide treatment and sequencing decisions for patients with metastatic melanoma.
Read More
A 66-Year-Old Man with Relapsed/Refractory Multiple Myeloma (RRMM)
October 23rd 2023Rafael Fonseca, MD, discusses treatment considerations for a 66-year-old man with relapsed/refractory multiple myeloma after several prior therapies, and highlights recent clinical trial results with novel BCMA-targeted bispecific antibodies and other therapies in the relapsed/refractory setting.
Read More